股票代码：600327 股票简称：大东方 公告编号：临 2023－034 无锡商业大厦大东方股份有限公司 2023 年半年度业绩说明会预告公告 重要内容提示： 无锡商业大厦大东方股份有限公司（以下简称"公司"）于 2023 年 8 月 23 日在上海证券交易所网站、《上海证券报》披露了公司 2023 年半年度报告。为使 广大投资者更深入了解公司 2023 年半年度经营成果、财务状况，公司计划于 2023 年 9 月 18 日（星期一）上午 11:00-12:00 通过网络平台在线交流的方式举行"无 锡商业大厦大东方股份有限公司 2023 年半年度业绩说明会"，就投资者关心的问 题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2023 年半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范 围内就投资者普遍关注的问题进行回答。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 二、说明会召开的时间、地点 （一）会议召开时间：2023 年 9 月 18 日（星期一） ...

无锡商业大厦大东方股份有限公司 关于以集中竞价交易方式回购股份的进展公告 公司于 2023 年 4 月 18 日召开第八届董事会第十一次会议，审议通过了《关 于以集中竞价交易方式回购公司股份方案的议案》，同意公司以自有资金通过集 中竞价交易方式回购公司股份，并将回购股份全部用于股权激励或员工持股计划。 回购资金总额不低于人民币 3,000 万元（含），不超过人民币 5,000 万元（含）， 回购价格不超过人民币 7.12 元/股（含），回购期限为自董事会审议通过本次回 购股份方案之日起 12 个月内。 有关本次回购股份事项具体情况详见公司于 2023 年 4 月 20 日在上海证券 报、上海证券交易所网站（http://www.sse.com.cn）披露的《大东方关于以集 中竞价交易方式回购公司股份方案的公告》（公告编号：2023-013），以及《大东 方关于以集中竞价交易方式回购股份的回购报告书》（公告编号：2023-019）。 一、公司回购股份进展情况 根据《上市公司股份回购规则》、《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，公司在回购股份期间，应当在每个月的前 3 个 交易日 ...

Financial Performance - The company's operating revenue for the first half of 2023 reached approximately CNY 1.76 billion, representing a 13.91% increase compared to the same period last year[20]. - Net profit attributable to shareholders decreased by 13.92% to approximately CNY 138.77 million compared to CNY 161.21 million in the previous year[20]. - The basic earnings per share for the first half of 2023 was CNY 0.157, down 13.74% from CNY 0.182 in the same period last year[20]. - The company achieved a revenue of 1.764 billion CNY and a net profit of 143.51 million CNY for the first half of 2023, with a net profit attributable to shareholders of 138.77 million CNY[27]. - Operating profit for the first half of 2023 was ¥166,877,158.90, down 16.1% from ¥199,023,701.80 in the first half of 2022[81]. - The company reported a total comprehensive income of 161,213,000 RMB for the current period, which is a significant increase from the previous period[96]. Cash Flow and Liquidity - The net cash flow from operating activities improved significantly, reaching approximately CNY 191.95 million, compared to a negative cash flow of CNY 61.39 million in the previous year, marking a 412.70% increase[20]. - The net cash flow from operating activities for the first half of 2023 was ¥157,723,872.94, a significant improvement compared to a net outflow of ¥37,052,029.49 in the same period of 2022[91]. - The company’s cash and cash equivalents increased to ¥470,519,682.09, up from ¥461,832,796.63, indicating a growth of 1.5%[81]. - The company’s cash and cash equivalents at the end of the first half of 2023 were CNY 454,003,005.79, down from CNY 700,029,458.99 at the end of the first half of 2022[88]. Assets and Liabilities - The total assets of the company increased by 2.10% to approximately CNY 5.68 billion compared to CNY 5.56 billion at the end of the previous year[20]. - The total liabilities increased to ¥2,222,670,323.13 from ¥2,157,069,116.54, reflecting an increase of about 3.04%[75]. - The company reported a total liability of ¥1,417,011,490.05, an increase of 8.8% from ¥1,302,598,029.38 in the previous year[81]. - The company’s total liabilities decreased by 149,026,000 RMB, indicating improved financial health[96]. Business Segments and Operations - The retail business segment generated a revenue of 370 million CNY, representing a 3.88% increase compared to the same period in 2022, while gross profit decreased by 3.26% to 136.91 million CNY[28]. - The "San Feng Qiao" food segment reported a revenue of 100.98 million CNY, marking a 45.31% year-on-year increase[30]. - The "San Feng Qiao" catering segment achieved a revenue of 30.68 million CNY, reflecting a 16.33% growth compared to the previous year[31]. - The medical health segment generated a revenue of 1.224 billion CNY, with a gross profit of 87 million CNY[31]. - The company opened 8 new stores in the Hubei 7-11 convenience store business, bringing the total to 34 stores, including 12 direct-operated and 22 franchised stores[28]. Strategic Focus and Future Plans - The company focused on enhancing its operational strategies in the retail sector, including member management and marketing efficiency, to maintain market share[27]. - The company is implementing a dual business strategy of "retail + medical health" to drive growth in both sectors[25]. - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[92]. Research and Development - Research and development expenses rose by 28.60% to ¥3,832,603.01, up from ¥2,980,178.23, indicating a focus on innovation[32]. - The company has not disclosed any plans for new product launches or technological developments in this report[20]. Shareholder and Equity Information - The company did not distribute any dividends or bonus shares for the first half of 2023, with a proposed distribution of 0 shares and 0 yuan per 10 shares[47]. - The total number of ordinary shareholders at the end of the reporting period is 39,739[64]. - The largest shareholder, Beida Daxia Materials Co., Ltd., holds 44.71% of the shares, totaling 395,552,372 shares[66]. Compliance and Governance - The company continues to face risks similar to those outlined in the 2022 annual report, with no significant changes reported during the current period[43]. - There were no significant lawsuits or arbitration matters reported during the reporting period[53]. - The company has not reported any non-operating fund occupation by major shareholders or related parties during the reporting period[52]. Financial Reporting and Accounting Policies - The financial report for the first half of 2023 was approved on August 22, 2023[108]. - The company adheres to the enterprise accounting standards, ensuring the financial statements reflect its financial status accurately[114]. - The company follows a control-based approach for preparing consolidated financial statements, including all subsidiaries in the consolidation scope[120].

股票代码：600327 股票简称：大东方 公告编号：临 2023－032 2、报告期内门店减少情况（4-6 月） | 地区 | 经营业态 | 门店名称 | 物业 | 建筑面积 | 减少时间 | 情况 | | --- | --- | --- | --- | --- | --- | --- | | | | | 权属 | (㎡) | | 说明 | | 江苏 | 超市 | 无锡商业大厦东方百业超市有限公 司康桥店 | 租赁 | 230 | 2023-04-12 | 注销 | | 江苏 | 食品专卖 | 无锡市三凤桥食品专卖有限责任公司 | 租赁 | 231 | 2023-04-18 | 注销 | | | 店 | 五爱店 | | | | | 3、报告期末门店分布情况 | 地区 | 经营业态 | 自有物业门店 | | 租赁物业门店 | | | --- | --- | --- | --- | --- | --- | | | | 门店数量 | 建筑面积(万平米) | 门店数量 | 建筑面积(万平米) | | 江苏 | 百货 | 1 | 8.0722 | 0 | 0 | | 江苏 | 超市 | 1 | 0.0947 | 5 | ...

表决结果：同意 7 票 反对 0 票 弃权 0 票 监事会发表意见如下： 1、公司 2023 年半年度报告编制和审议程序符合法律、法规、公司章程和公 司内部管理制度的各项规定； 2、公司 2023 年半年度报告的内容和格式符合中国证监会和证券交易所的各 项规定，所包含的信息能从各个方面真实地反映公司报告期的经营管理和财务状 况等事项； 股票代码：600327 股票简称：大东方 公告编号：临 2023－031 无锡商业大厦大东方股份有限公司 第八届监事会第十三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 无锡商业大厦大东方股份有限公司第八届监事会第十三次会议于 2023 年 8 月 22 日以通讯表决方式召开。本次监事会应参与审议监事 7 人，实际参加审议 表决监事 7 人。会议召开符合《公司法》和《公司章程》的规定。会议审议并通 过了以下议案： 一、《2023 年半年度报告》 二、《2023 年半年度经营数据简报》 表决结果：同意 7 票 反对 0 票 弃权 0 票 特此公告。 无锡商业大厦大东方股份有 ...

一、《2023 年半年度报告》 表决结果：同意 9 票 反对 0 票 弃权 0 票 股票代码：600327 股票简称：大东方 公告编号：临 2023－030 无锡商业大厦大东方股份有限公司 第八届董事会第十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 无锡商业大厦大东方股份有限公司第八届董事会第十三次会议于 2023 年 8 月 22 日以通讯表决方式召开。本次董事会应参与审议董事 9 人，实际参加审议 表决董事 9 人。会议召开符合《公司法》和《公司章程》的规定。会议审议并通 过了以下议案： 特此公告。 无锡商业大厦大东方股份有限公司董事会 2023 年 8 月 23 日 1 二、《2023 年半年度经营数据简报》 表决结果：同意 9 票 反对 0 票 弃权 0 票 ...

股票代码：600327 股票简称：大东方 公告编号：临 2023－023 无锡商业大厦大东方股份有限公司 2022 年度暨 2023 年第一季度业绩说明会预告公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 无锡商业大厦大东方股份有限公司（以下简称"公司"）分别于 2023 年 4 月 20 日、2023 年 4 月 28 日在上海证券交易所网站、《上海证券报》披露了公司 2022 年年度报告和 2023 年第一季度报告。为使广大投资者更深入了解公司 2022 年度及 2023 年第一季度经营成果、财务状况，公司计划于 2023 年 6 月 1 日（星 期四）上午 9:00-10:00 通过网络平台在线交流的方式举行"无锡商业大厦大东 方股份有限公司 2022 年度暨 2023 年第一季度业绩说明会"，就投资者关心的问 题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2022 年度及 2023 年一 季度的经营成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披 ...

Financial Performance - The company's operating revenue for Q1 2023 was ¥909,421,991.74, representing a year-on-year increase of 5.96%[3] - The net profit attributable to shareholders decreased by 55.03% to ¥25,748,899.42 compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses fell by 66.08% to ¥13,401,626.32[3] - The basic and diluted earnings per share were both ¥0.029, reflecting a decrease of 55.03% year-on-year[4] - Net profit for Q1 2023 was ¥47,006,187.44, down from ¥91,493,981.47 in Q1 2022, indicating a decline of 48.7%[15] - The net profit for Q1 2023 was ¥27,099,128.83, a decrease of 60.9% compared to ¥69,320,742.86 in Q1 2022[16] - The net profit attributable to shareholders of the parent company was ¥25,748,899.42, down 55.1% from ¥57,257,514.55 in the previous year[16] - The total comprehensive income for Q1 2023 was ¥35,574,139.03, a decline of 48.6% from ¥69,108,867.60 in Q1 2022[16] - The basic and diluted earnings per share for Q1 2023 were both ¥0.029, compared to ¥0.065 in Q1 2022, representing a decrease of 55.4%[16] Cash Flow and Investments - The net cash flow from operating activities was ¥202,040,894.22, with no applicable year-on-year comparison[3] - Cash inflows from operating activities totaled ¥1,326,466,460.68, down 9.1% from ¥1,459,197,692.06 in the same period last year[18] - The net cash flow from operating activities was ¥202,040,894.22, a significant improvement from a net outflow of -¥26,218,840.44 in Q1 2022[18] - The net cash flow from investing activities was -¥124,328,006.74, compared to -¥156,026,125.89 in the previous year, indicating a reduced cash outflow[19] - The net cash flow from financing activities was ¥35,618,796.69, a recovery from a net outflow of -¥220,968,597.09 in Q1 2022[19] - The cash and cash equivalents at the end of Q1 2023 were ¥592,297,013.15, an increase from ¥1,168,196,437.06 at the end of Q1 2022[19] Assets and Liabilities - The total assets at the end of the reporting period were ¥5,584,802,377.78, an increase of 1.67% from the end of the previous year[3] - Total assets as of March 31, 2023, amounted to ¥5,584,802,377.78, an increase from ¥5,492,937,354.40 at the end of December 2022[12] - Total liabilities increased to ¥2,146,990,296.58 in Q1 2023 from ¥2,091,401,736.16 in Q4 2022, reflecting a rise of 2.7%[12] - Non-current assets totaled ¥4,438,187,380.81 as of March 31, 2023, slightly down from ¥4,383,733,677.10 at the end of December 2022[11] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 47,361[6] - The equity attributable to shareholders increased by 1.08% to ¥3,237,093,377.02 compared to the end of the previous year[3] Operational Metrics - Operating costs for Q1 2023 were ¥857,333,793.24, up from ¥794,616,841.72 in Q1 2022, reflecting a rise of 7.9%[15] - The company reported non-recurring gains of ¥12,347,273.10, primarily from government subsidies and other income[4] - The decline in net profit was mainly due to reduced investment income from associates and the impact of negative goodwill from a medical business acquisition[4] - Accounts receivable rose to ¥142,043,210.53 in Q1 2023, up from ¥88,118,064.56 in Q4 2022, marking a significant increase of 60.9%[10] - Inventory decreased to ¥241,328,362.88 in Q1 2023 from ¥258,696,835.70 in Q4 2022, a reduction of 6.7%[10] - The company reported R&D expenses of ¥2,524,297.22 in Q1 2023, indicating ongoing investment in innovation[15]

Financial Performance - The company achieved a net profit of ¥190,206,150.52 for the year 2022, with a net profit attributable to shareholders of ¥174,263,895.76[5]. - The company's operating revenue for 2022 was ¥3,129,578,603.35, a decrease of 54.68% compared to ¥6,904,813,130.77 in 2021[24]. - The net profit attributable to shareholders for 2022 was ¥174,263,895.76, down 72.80% from ¥640,589,073.77 in 2021[24]. - The basic earnings per share for 2022 was ¥0.197, a decline of 72.79% compared to ¥0.724 in 2021[25]. - The company reported a net cash flow from operating activities of -¥140,234,049.02 in 2022, a decrease of 121.77% from ¥644,296,084.33 in 2021[24]. - The total assets at the end of 2022 were ¥5,492,937,354.40, down 33.45% from ¥8,253,970,595.74 at the end of 2021[24]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was only ¥9,889,321.32 in 2022, a significant drop of 93.43% from ¥150,577,510.64 in 2021[24]. Dividend Distribution - The proposed cash dividend is ¥0.70 per 10 shares, resulting in a total distribution of ¥61,934,566.26, which represents a cash dividend payout ratio of 35.54%[5]. - The board of directors has approved the profit distribution plan, which is subject to the approval of the annual general meeting[6]. - The total cash dividend amount distributed was 61,934,566.26 RMB, representing 35.54% of the net profit attributable to ordinary shareholders in the consolidated financial statements[174]. Acquisitions and Expansion - The company completed three acquisitions in the healthcare sector during 2022, including an 80% stake in "Jinhua Lianji Hospital" and a 68.1851% stake in "Zhibei Medical"[33]. - The pediatric healthcare business expanded to nearly 50 children's service chain institutions across more than 30 major cities in China[34]. - The company expanded its medical health services, acquiring "Zhibei Medical" and "Jinhua Lianji Hospital," and further increasing its stake in "Jiankao Pediatrics" to enhance its healthcare service capabilities[54]. - The company aims to focus on pediatric healthcare, targeting sub-specialties such as pediatric endocrinology and psychology, and aims to enhance the asset and revenue structure of the healthcare business[133]. Operational Efficiency and Cost Management - The company is restructuring its organization to enhance operational efficiency, aiming for a streamlined and flexible structure to improve management effectiveness[47]. - The company has implemented cost reduction and efficiency enhancement measures, focusing on investment evaluation and dynamic tracking of new projects, leading to improved profitability[49]. - The company is focused on enhancing its operational efficiency by optimizing approval processes and reducing hidden costs[49]. - The company has optimized its supermarket and convenience store models, achieving a new product launch rate of 10% with 856 new SKUs, while closing underperforming stores to enhance profitability[42]. Risk Management and Compliance - The company has outlined potential risks in its management discussion and analysis section, emphasizing the importance of investor awareness regarding these risks[8]. - The company has established a comprehensive internal control system, transitioning from compliance audits to management audits, enhancing risk control measures and compliance awareness[50]. - The company has confirmed that there are no non-operational fund occupations by controlling shareholders or related parties[8]. - The company has not reported any violations of decision-making procedures regarding external guarantees[8]. Market Trends and Strategic Focus - The company plans to focus on pediatric and orthopedic healthcare, capitalizing on favorable policies and the growing demand for children's medical services[118]. - The healthcare sector is expected to see increased competition from public hospitals, necessitating improvements in management and service quality for private healthcare providers[118]. - The macroeconomic policies in 2023 emphasize expanding domestic demand and improving consumption conditions, setting a positive tone for the retail industry[106]. - The orthopedic market is experiencing strong demand, with a focus on chronic bone disease management and rehabilitation services for adolescents and the elderly[119]. Employee and Management Structure - The company has a total of 2,747 employees, with 454 in the parent company and 2,293 in major subsidiaries[167]. - The technical staff comprises 1,091 employees, representing a significant portion of the workforce[167]. - The company has implemented a salary policy that emphasizes performance and competitiveness, aligning compensation with economic indicators[168]. - The company has established a performance evaluation and incentive mechanism for senior management, linking performance pay to annual profit and operational performance[175]. Corporate Governance - The audit committee held 6 meetings during the reporting period, addressing key financial reports and internal control evaluations[163]. - The board of directors held a total of 8 meetings throughout the year, ensuring active governance[160]. - The company has no reported penalties from securities regulatory agencies in the past three years[159]. - There were no dissenting opinions raised by the board members regarding company matters during the reporting period[162].

Key Financial Data [Key Accounting Data and Financial Indicators](index=1&type=section&id=%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E5%92%8C%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87) The company's core financial indicators declined significantly year-over-year in Q3 2022 and the year-to-date period Key Financial Indicators for Q3 2022 and Year-to-Date | Item | Current Reporting Period (RMB) | YoY Change for the Period (%) | Year-to-Date (RMB) | YoY Change for Year-to-Date (%) | | :--- | :--- | :--- | :--- | :--- | | **Operating Revenue** | 788,396,668.49 | -56.71 | 2,336,713,855.52 | -61.50 | | **Net Profit Attributable to Shareholders** | 12,881,837.58 | -94.85 | 172,039,703.81 | -57.17 | | **Net Profit Attributable to Shareholders (Excluding Non-recurring Items)** | -28,540,936.67 | -595.99 | 11,324,493.04 | -90.95 | | **Net Cash Flow from Operating Activities** | N/A | N/A | -96,497,865.73 | -122.33 | | **Basic EPS (RMB/Share)** | 0.015 | -94.85 | 0.194 | -57.17 | | **Total Assets** | 5,806,299,763.77 | - | 8,253,970,595.74 (End of Prior Year) | -29.65 | | **Equity Attributable to Shareholders** | 3,393,822,637.56 | - | 3,599,088,859.93 (End of Prior Year) | -5.70 | [Non-recurring Profit and Loss Items and Amounts](index=2&type=section&id=%E9%9D%9E%E7%BB%8F%E5%B8%B8%E6%80%A7%E6%8D%9F%E7%9B%8A%E9%A1%B9%E7%9B%AE%E5%92%8C%E9%87%91%E9%A2%9D) Year-to-date non-recurring profit and loss totaled RMB 161 million, mainly from the disposal of non-current assets Year-to-Date Non-recurring Profit and Loss Items | Item | Year-to-Date Amount (RMB) | | :--- | :--- | | Gains/Losses from Disposal of Non-current Assets | 149,926,721.98 | | Government Grants in Current P&L | 6,413,078.93 | | Gains from Acquisition of Subsidiaries | 17,122,759.41 | | Gains/Losses from Debt Restructuring | 4,440,545.16 | | Other Non-operating Income/Expenses | 2,115,745.30 | | **Total** | **160,715,210.78** | [Analysis of Changes in Key Financial Indicators](index=2&type=section&id=%E4%B8%BB%E8%A6%81%E4%BC%9A%E8%AE%A1%E6%95%B0%E6%8D%AE%E3%80%81%E8%B4%A2%E5%8A%A1%E6%8C%87%E6%A0%87%E5%8F%91%E7%94%9F%E5%8F%98%E5%8A%A8%E7%9A%84%E6%83%85%E5%86%B5%E3%80%81%E5%8E%9F%E5%9B%A0) Significant fluctuations in key financial indicators were driven by business restructuring, including the disposal of the auto business - The sharp decline in core indicators such as operating revenue, net profit, and operating cash flow is mainly attributable to **major adjustments in the company's business structure**, including the addition of a medical business and the disposal of the auto business[4](index=4&type=chunk) - The significant year-over-year drop in net profit attributable to shareholders and net profit excluding non-recurring items was primarily due to the combined effect of the **disposal of the auto business in the prior year** and the **disposal of Junxu Real Estate in the current period**[4](index=4&type=chunk) Shareholder Information [Shareholder Holdings](index=3&type=section&id=%E6%99%AE%E9%80%9A%E8%82%A1%E8%82%A1%E4%B8%9C%E6%80%BB%E6%95%B0%E5%92%8C%E8%A1%A8%E5%86%B3%E6%9D%83%E6%81%A2%E5%A4%8D%E7%9A%84%E4%BC%98%E5%85%88%E8%82%A1%E8%82%A1%E4%B8%9C%E6%95%B0%E9%87%8F%E5%8F%8A%E5%89%8D%E5%8D%81%E5%90%8D%E8%82%A1%E4%B8%9C%E6%8C%81%E8%82%A1%E6%83%85%E5%86%B5%E8%A1%A8) The company had 39,937 common shareholders, with the largest shareholder holding a 44.71% stake - At the end of the reporting period, the company had a total of **39,937 common shareholders**[6](index=6&type=chunk) Top Five Shareholders' Holdings | Shareholder Name | Shareholder Type | Number of Shares Held | Shareholding Ratio (%) | | :--- | :--- | :--- | :--- | | Jiangsu Wuxi Commercial Building Group Co., Ltd. | Domestic Non-state-owned Legal Entity | 395,552,372 | 44.71 | | Fullgoal CSI Dividend Index Enhanced Securities Investment Fund | Other | 23,128,536 | 2.61 | | Dacheng CSI Dividend Index Securities Investment Fund | Other | 11,229,752 | 1.27 | | E Fund CSI Dividend ETF | Other | 6,942,420 | 0.78 | | Basic Pension Insurance Fund Portfolio 1005 | Other | 5,434,221 | 0.61 | - The company's controlling shareholder, Jiangsu Wuxi Commercial Building Group Co., Ltd., and the company's chairman, Gao Binghua, are **parties acting in concert**[7](index=7&type=chunk) Quarterly Financial Statements [Consolidated Balance Sheet](index=5&type=section&id=%E5%90%88%E5%B9%B6%E8%B5%84%E4%BA%A7%E8%B4%9F%E5%80%BA%E8%A1%A8) Total assets and liabilities contracted significantly due to business restructuring, primarily the disposal of the auto business Key Items from the Consolidated Balance Sheet (as of Sep 30, 2022) | Item | Sep 30, 2022 (RMB) | Dec 31, 2021 (RMB) | Change (%) | | :--- | :--- | :--- | :--- | | **Total Assets** | **5,806,299,763.77** | **8,253,970,595.74** | **-29.65** | | Cash and Cash Equivalents | 731,375,787.29 | 1,665,443,275.09 | -56.08 | | Inventories | 252,429,971.35 | 2,229,129,537.26 | -88.68 | | Long-term Equity Investments | 1,973,644,696.49 | 1,608,351,445.97 | 22.71 | | **Total Liabilities** | **2,196,985,618.79** | **4,335,970,455.65** | **-49.33** | | Contract Liabilities | 205,511,071.65 | 1,491,490,856.24 | -86.22 | | **Total Equity Attributable to Parent Company** | **3,393,822,637.56** | **3,599,088,859.93** | **-5.70** | [Consolidated Income Statement](index=8&type=section&id=%E5%90%88%E5%B9%B6%E5%88%A9%E6%B6%A6%E8%A1%A8) Year-to-date revenue and net profit declined due to the high base from the disposed auto business in the prior year Key Items from the Consolidated Income Statement (First Three Quarters of 2022) | Item | First Three Quarters 2022 (RMB) | First Three Quarters 2021 (RMB) | YoY Change (%) | | :--- | :--- | :--- | :--- | | **Total Operating Revenue** | **2,336,713,855.52** | **6,069,759,294.71** | **-61.50** | | Total Operating Costs | 2,264,788,960.94 | 5,896,863,651.66 | -61.59 | | Investment Income | 148,376,029.28 | 442,784,832.02 | -66.50 | | **Total Profit** | **239,702,879.59** | **646,291,385.44** | **-62.91** | | **Net Profit Attributable to Parent Company Shareholders** | **172,039,703.81** | **401,674,293.07** | **-57.17** | | **Basic EPS (RMB/Share)** | **0.194** | **0.454** | **-57.27** | [Consolidated Cash Flow Statement](index=11&type=section&id=%E5%90%88%E5%B9%B6%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) Operating cash flow turned negative year-to-date due to reduced cash from sales following business restructuring Key Items from the Consolidated Cash Flow Statement (First Three Quarters of 2022) | Item | First Three Quarters 2022 (RMB) | First Three Quarters 2021 (RMB) | YoY Change (%) | | :--- | :--- | :--- | :--- | | **Net Cash Flow from Operating Activities** | **-96,497,865.73** | **432,118,207.48** | **-122.33** | | Cash Received from Sales of Goods and Services | 3,370,850,341.46 | 8,593,442,657.81 | -60.78 | | **Net Cash Flow from Investing Activities** | **-494,186,007.94** | **121,700,777.83** | **-506.07** | | **Net Cash Flow from Financing Activities** | **-434,158,881.38** | **-149,444,955.73** | **-190.65** | | **Net Increase in Cash and Cash Equivalents** | **-1,024,842,755.05** | **404,374,029.58** | **-353.44** | | **Cash and Cash Equivalents at Period-End** | **546,567,245.43** | **1,286,854,092.32** | **-57.53** |